Intrepid Labs Launches to Transform Drug Formulation with AI and Autonomous Labs
Article content
TORONTO — Intrepid Labs, a biotechnology company transforming drug formulation development through the use of artificial intelligence (AI) and robotics, emerged from stealth today to accelerate therapeutics development through effective formulations that improve clinical performance.
Article content
The company has secured several industry partners, and recently closed a $7 million USD seed round led by AVANT BIO, which follows a $4 million USD unannounced pre-seed round led by Radical Ventures, with participation from Propagator Ventures. The proceeds from these financings will expand Intrepid Labs' team, accelerate the development of its proprietary delivery technologies, and scale commercial operations to keep pace with customer demand.
Article content
'It is apparent that traditional approaches to drug formulation aren't working,' said Christine Allen, co-founder and chief executive officer of Intrepid Labs. 'Pharma companies are relying on legacy approaches that fail to deliver the best possible formulations into the clinic. I believe this contributes to the high rate of failure during clinical development. Intrepid Labs is addressing this overlooked bottleneck in drug development with its transformative approach that unlocks a faster, more precise path to improve the quality of therapeutics. We're going to change the way the industry thinks about drug formulation.'
Article content
Formulation is a critical step in drug development. Effective formulations not only improve therapeutic efficacy, but also mitigate adverse effects, enhancing overall patient safety, while improving drug development success rates.
Article content
The conventional approach to formulation design is slow and expensive. It starts with benchmarks from existing formulations and then proceeds, one parameter at a time, through a trial-and-error exercise. As a result, companies often settle for suboptimal formulations that fail to maximize a drug's performance, leaving most of the design space untapped.
Article content
Intrepid Labs is transforming drug formulation with its Valiant™ platform – a modular, AI-driven robotic lab that rapidly explores the full formulation design space. Starting with an active pharmaceutical ingredient and a target product profile, Valiant selects, prepares, and analyzes formulations through semi- and fully autonomous workflows, refining multiple parameters in parallel with expert oversight. What once took months can now be achieved in days – delivering optimized formulations through a comprehensive, data-driven process.
Article content
Since its founding in 2023, Intrepid Labs has forged partnerships with multiple drug developers, including some of the largest global pharmaceutical companies, as well as contract research organizations, and small and mid-sized biotechs. Industry partners use the Valiant platform to identify optimized formulations and accelerate drug development. At the same time, Intrepid Labs is developing its own proprietary oral and long-acting injectable delivery technologies for small molecules and biologics that are available for licensing.
Article content
'Intrepid Labs is unlocking a new era in drug formulation, in which delivery format, dosing frequency, and patient experience can be intentionally designed from day one,' said Sebastien Latapie, partner at AVANT BIO. 'By using AI and robotics to screen vast formulation possibilities, its Valiant platform enables more cost-effective therapies and better outcomes for patients.'
Article content
About Intrepid Labs
Article content
Intrepid Labs was spun out of the University of Toronto to pioneer the use of artificial intelligence and robotics to redefine drug formulation and accelerate therapeutic development. The company is led by CEO and co-founder Dr. Christine Allen, a global expert in drug formulation with over 180 peer-reviewed publications. Together with co-founders Dr. Pauric Bannigan (chief scientific officer) and Dr. Riley Hickman (director of research and development), Intrepid's leadership team leverages expertise in drug delivery, laboratory automation, and AI-driven formulation.
Article content
Intrepid partners with leading pharmaceutical companies, CROs, CDMOs, and biotechs to accelerate research and development (R&D) and enhance formulation strategies. The company is also advancing an internal pipeline of proprietary drug delivery technologies available for licensing. Based in the MaRS Discovery District in Toronto, Intrepid is reshaping how the industry approaches drug formulation R&D. Companies with active pharmaceutical ingredients or candidates requiring formulation solutions are encouraged to contact Intrepid at info@intrepidlabs.ai.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact
Maggie Williard
Account Executive, HDMZ
maggie.williard@hdmz.com
(312) 506-5239
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
an hour ago
- Toronto Star
Developers unveil plans for aviation-themed playground on former Downsview Airport lands
A Toronto-based developer unveiled plans to convert a 100-foot decommissioned airplane into a playground on former Downsview Airport lands on Monday. The deconstructed plane, or 'playscape,' is part of a larger project including a public plaza at YZD, the community planned for the redevelopment of North York's former 370-acre airport.
Globe and Mail
an hour ago
- Globe and Mail
Meta Is Making a Big Bold Investment of Over $10B in Scale AI
Meta Platforms (META) is reportedly in talks to invest over $10 billion in artificial intelligence (AI) startup Scale AI. The news was first reported by Bloomberg, citing people familiar with the matter. If finalized, this investment would represent a significant shift for Meta, marking its largest external funding commitments to date. It would also be one of the largest private-sector funding deals in the AI sector to date. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The terms of the deal remain unknown and are subject to change. The startup was valued at $13.8 billion in its most recent funding round, in which Meta, Nvidia (NVDA), and Amazon (AMZN) had participated. Bloomberg had reported earlier this year, that Scale AI was in talks for another funding round, potentially valuing the company at roughly $25 billion. Meta Is Investing Billions in Scale AI Scale AI was founded in 2016 by CEO Alexandr Wang. The company specializes in data labeling: assigning labels/tags to images, text, and other data used for training AI models. Scale AI has been growing rapidly and has become one of the prime beneficiaries of the generative AI revolution. In 2024, Scale AI generated revenue of $870 million and is set to more than double its sales this year to reach $2 billion. Scale AI serves a diverse set of customers, including Microsoft (MSFT), ChatGPT maker OpenAI, and the U.S. Department of Defense. The company uses a vast network of contract workers to scan, organize, and label troves of datasets, thus facilitating efficient AI model training. This process is crucial, since machine learning models require the usage and input of enormous amounts of data, and Scale AI's services enable companies to train their models more swiftly and with greater precision. Meta Is Going All-In on AI Meanwhile, Meta is going all-in on AI investments. It has committed to invest up to $65 billion in AI related projects this year. Although Meta does not operate its own cloud services platform, it has developed a successful series of large language AI models called Llama. Meta's Llama chatbot is used by approximately 1 billion users per month on its Facebook, Instagram, and WhatsApp apps. Notably, Meta and Scale AI have also partnered earlier to develop the Defense Llama model for the government. Moreover, Meta's AI models are used by U.S. government agencies and defense contractors for military applications. Last week, Meta also struck a 20-year deal with nuclear energy company Constellation Energy (CEG) to buy green credits from its Illinois nuclear plant, effective 2027. This deal ensures a stable and sustainable energy supply for Meta's massive AI and data center operations, supporting its commitment to achieving net-zero emissions. Is META a Good Company to Buy? Wall Street remains highly optimistic about Meta Platforms' long-term stock trajectory. On TipRanks, META stock has a Strong Buy consensus rating based on 41 Buys, three Holds, and one Sell rating. Also, the average Meta Platforms price target of $697.55 implies that shares are almost fully valued at current levels. Year-to-date, META stock has gained 19.3%. See more META analyst ratings
CTV News
an hour ago
- CTV News
SAAQclic ‘bumpy' as early as 2018, witness tells Gallant commission
The Gallant Commission, tasked with investigating the failures of the Société de l'assurance automobile du Québec (SAAQ) IT transition, on May 15, 2025, in Quebec City. (The Canadian Press/Jacques Boissinot) The digital transition at Quebec's automobile insurance board (SAAQ) was already 'bumpy' in 2018, the commission investigating the SAAQclic fiasco heard Monday. Sylvain Cloutier, director of the project office, testified before the Gallant commission, which travelled to Quebec City to begin its sixth week of hearings. He spoke about the coloured indicators used by his team to track progress — markers that, without clear explanation, often shifted from red to green. 'When things become increasingly chaotic, doesn't accountability matter?' asked Justice Denis Gallant, pressing Cloutier on his apparent lack of control over how the colours were assigned. Cloutier said the indicators 'on their own weren't enough' to give a full picture of the project's status. The board's vice-president of information technology, Karl Malenfant, would regularly step in to offer 'explanations.' Malenfant's name has surfaced repeatedly over the past six weeks at the Gallant commission. 'There were problems, but Mr. Malenfant didn't try to hide them,' said Cloutier. 'He's an experienced man. He's led major projects at Hydro-Québec, at Rio Tinto. He knows what he's talking about. He came in to explain things and reassure the team — not reassure as in spinning stories,' Cloutier added. 'Was everyone aware?' commission lawyer Vincent Ranger asked. 'Was Mr. Malenfant transparent about how difficult the rollout was?' 'Yes,' Cloutier replied. 'Would it be fair to say Mr. Malenfant is naturally optimistic?' Ranger followed up. 'Yes, that's true,' Cloutier said. 'But not in a head-in-the-clouds way. He likes a challenge.' 'I didn't take bribes' Cloutier also admitted Monday to manipulating a public tender worth over $1 million so it would be awarded to external consultant Stéphane Mercier. 'That was my mistake,' Cloutier acknowledged under questioning from Justice Gallant. 'I'm not saying what I did was right. But I take responsibility — it was me.' In 2017, Cloutier urgently requested the bidding threshold be lowered to $990,000 after Mercier informed him he couldn't qualify for the contract because he didn't have authorization from Quebec's financial markets authority. That authorization is required for contracts valued at more than $1 million. 'I was in a panic,' Cloutier said, recalling thinking, 'If I don't have this guy to keep going, we're in deep trouble (…) I'm losing expertise.' 'I did it with the intention of not delaying the project,' he said. 'I didn't take any bribes. I'm not going on fishing trips. I'm not sailing around on a yacht. That's not what this is.' This report by The Canadian Press was first published in French June 9, 2025.
